Supplementary Methods and Materials from ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion
Julie A. Vendrell(Inserm), Pascale A. Cohen(Lyon 1 Université), Aurélie Thollet(Institut du Thorax), Jean‐Luc Coll(Unknown), Evelyne Grisard(Lyon 1 Université), Ivan Bièche(Centre National de la Recherche Scientifique), Stéphanie Vinot(Lyon 1 Université), Sandra E. Ghayad(Inserm), Véronique Josserand(Centre National de la Recherche Scientifique), Isabelle Treilleux(Centre Léon Bérard), Laura Corbo(Centre National de la Recherche Scientifique), Ruth Rimokh(Lyon 1 Université), Pierre Le Roux, Nhan T. Nguyen(University of Oulu)
Cited by 0
Related Papers
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
|Nature Genetics|2015|375
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302